DOCSLIB.ORG

Vaccines Innovative

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Vaccines Innovative 2013 MeDiciNes iN DeVelopmeNT REPORT Vaccines A Report on the Prevention and Treatment of Disease Through Vaccines PRESENTED BY AMERICA’s biopharmACEUTICAL RESEARCH COMPANIES Nearly 300 Vaccines Are in Development; Research Focuses on Prevention and Treatment For many years, vaccines have been used • A monoclonal antibody vaccine that to successfully prevent devastating infec- targets both pandemic and seasonal tious diseases such as smallpox, measles influenza. and polio. According to data from the • A genetically-modified vaccine designed Vaccines in Development* U.S. Centers for Disease Control and for the treatment of pancreatic cancer. Prevention (CDC), 10 infectious diseases Application Submitted have been at least 90 percent eradicated • An irradiated vaccine for protection in the United States thanks to vaccines. Phase III against malaria. This has protected millions of children Phase II and families from needless illness. The development and regulatory path that these vaccine candidates face is Phase I These public health triumphs illustrate the complex. As with the development of all major contributions that vaccines have drugs, the majority of vaccines must pre- 137 made in saving countless lives around vail through years of clinical testing before the world. In the past several years, they can be approved for use by the gen- through our growing understanding of eral public. However, advances in other the molecular underpinnings of disease scientific fields, such as genomics and and technological advances, many new manufacturing technologies, are becom- vaccines have been developed, including ing increasingly useful in the development one against human papillomavirus (HPV) of new vaccines. The continued efforts 99 infections that can lead to cervical cancer, of researchers within biopharmaceutical a vaccine to guard against the anthrax companies and across the ecosystem, virus before exposure, and a vaccine to who are pursuing new techniques and prevent pneumococcal infections in high- strategies in vaccine development, cre- risk populations. ate tremendous opportunities to protect against many more life-threatening But vaccines are not only for preventing diseases in the future. infectious diseases, some help the body fight a range of illnesses by activating the immune system to recognize and at- contents tack disease. In 2010, a new cancer vac- Innovative Vaccines in the Pipeline .................2 cine for the treatment of prostate cancer Preventative Vaccines: Positive Impact ...........3 was approved in the United States, and many more immunotherapeutic vaccines Scientific Advances in Vaccine Development .... 4 are in development. Vaccine Successes in the United States ........6 15 13 Vaccines in Development .......................... 10 10 Today, biopharmaceutical research com- Glossary ...................................................33 panies are developing 271 vaccines for Drug Development/Approval Process ........36 infectious diseases, cancer, neurological s gy er disorders, allergies and other diseases. der Other Aller Canc ectious ological Among the projects in development are: Disor Inf Diseases Neur • A therapeutic vaccine for HIV infection *Some vaccines are listed in more than one category. intended to delay disease progression. Key Issues innovative Vaccines in the Pipeline of the parasite is enough to cause an immune response, but not cause the disease, thus leading to protection against any Building on the transformational successes to date, the future malarial bite infection. future of vaccines—both for the prevention and treatment of disease—offers great hope for improving and preserving c ervical cancer—A live, attenuated Listeria monocyto- public health in the United States and across the globe. The genes (LM)-based immunotherapy is in development for 271 medicines in development span a wide array of diseases, the treatment of women who already have cervical cancer and employ exciting new scientific and technical knowledge. as a result of infection by the human papillomavirus (HPV). Here are a few examples of the promising vaccines in the The vaccine targets the HPV gene E7, which is responsible pipeline: for the transformation of HPV-infected cells into dysplastic or malignant tissue. The vaccine is engineered to secrete a Malaria—A malaria vaccine in development has shown to fusion protein that instructs the body’s immune system to be 100 percent effective in early clinical trials in preventing destroy the tumors. the transmission of the disease from infected mosquitoes to humans. The vaccine builds on initial knowledge gained in HIV Infection—A therapeutic vaccine in development is tar- the 1970s, where researchers demonstrated that long-term geting the low-mutating (conserved) parts from the protein protection against malaria was possible when volunteers p24 of the HIV virus. The vaccine consists of four peptides received thousands of bites from radiated infected mosqui- that are modified to increase the immune response against toes. The vaccine in development uses a weakened form of the conserved parts of the p24 protein. A sustained immune the whole sporozoite, a life-stage of the parasite Plasmo- response against the p24 protein has shown to be associ- dium falciparnum that causes malaria. This weakened form ated with delayed disease progression. Milestones in Vaccine Development 2013 egg-free vaccine first therapeutic 2010 cancer vaccine (U.S.) 2007 avian flu vaccine 2003 nasal flu vaccine hepatitis B vaccine 1981 polio vaccine 1952 rabies vaccine 1885 first vaccine ever developed is for smallpox 1796 2 Medicines in Development Vaccines 2013 Key Issues influenza—A monoclonal antibody (mAb) vaccine in and is a fully synthetic nanoparticle vaccine engineered to development targets both pandemic and severe seasonal mimic the properties of natural pathogens to elicit an im- influenza A virus infections. The mAb vaccine, made from mune response. recombinant human antibodies from human B-cell cultures, specifically targets the M2 protein of the virus, which is es- sential for the influenza virus to function normally. “More than two-thirds of new vaccines developed in the last 25 years have been Pancreatic cancer–A potential treatment for pancreatic developed from the United States.” cancer is a combination of two therapeutic vaccines. The Source: PhRMA 2013 Vaccine Fact Book treatment combines a Listeria-based vaccine that has been engineered to express the tumor-associated antigen mesothelin and allogeneic pancreatic cancer cells that are Preventative Vaccines: genetically-modified to secrete the immune-stimulant, Positive impact to Health and society granulocyte-macrophage colony stimulating factor (GM-CSF). The cells are irradiated to prevent further cell growth Vaccines are one of the most profound achievements of bio- although they stay metabolically active. Sequential adminis- medical science and public health. Spanning more than 200 tration of the vaccines in animal studies have demonstrated years of research and development, 10 infectious diseases enhanced tumor-specific T-cell and anti-tumor responses. have been at least 90 percent eradicated in the United States thanks to vaccines. This has protected millions of children s moking cessation–One in a new class of targeted vac- and families from avoidable illness. cines in development induces an antigen-specific immune activation for smoking cessation and relapse prevention. The prevention of disease has an enormous impact on the It is made from biocompatible and biodegradable materials health of individuals, but also the health of communities and RESEARCH & HOPE AWARDS On September 11, 2013, PhRMA, along with distinguished members of the medical, patient, and provider communities, presented the second annual Research & Hope Awards. This year’s program highlighted the history, progress and promising future of vaccines and immunization. PhRMA proudly presented the following awards: T he Research & Hope Award for Academic or Public Research in Vaccine Development Presented to individuals or a team from academic or government institutions for outstanding research in the area of vaccine development. 2013 award presented to: Douglas R. Lowy, M.D., and John T. Schiller, Ph.D., National Cancer Institute T he Research & Hope Award for Biopharmaceutical Industry Research in Vaccine Development Presented to individuals or team from a biopharmaceutical company for outstanding research in the area of vaccine development. 2013 award presented to: GlaxoSmithKline Malaria Vaccine Team T he Research & Hope Award for Patient and Community Health Presented to an individual or organization that has had a significant impact educating parents, health care providers or students about the importance of childhood immunizations and facilitating increased vaccinations in their community. 2013 award presented to: Linda Y. Fu, M.D., Children’s National Medical Center To learn more about the dedicated researchers honored with the 2013 Research & Hope Awards, please visit www.phrma.org/awards. Medicines in Development Vaccines 2013 3 Key Issues economies by reducing health care costs and avoiding lost pro- Today, there are 204 active clinical trials for vaccines, in- ductivity. Preventative vaccines are given to individuals, but see cluding 107 that have not yet started recruiting patients or their greatest benefit when entire populations are immunized. are just now seeking volunteers to participate and another When a high level of vaccination is achieved
Load more

Recommended publications
  • Fact Sheet: COVID Vaccines & Fetal Cell Lines
    Fact Sheet: COVID Vaccines & Fetal Cell Lines What is a fetal cell line? A cell taken from an aborted baby is multiplied into many cells of the same kind. These can be grown indefinitely and further multiplied, creating lines of cells that are sometimes used for science experiments. Fetus Kidney Tissue Human Cell Fetal Cell Line Expand and Multiply How are fetal cell lines used in vaccines? Fetal cell lines have been used to grow viruses and then create inactive viruses for vaccines. Historical fetal cell lines (WI-38 and MRC-5) derived in the 1960’s and 1970’s were used to create vaccines for diseases such as Rubella, Hepatitis A, and rabies. These and other historical cell lines (HEK293 and PER.C6) are sometimes used today in the creation of vaccines. Any vaccine that relies on these historic cell lines will not require new abortions. Are fetal cell lines necessary for vaccines? Most vaccines use non-human cells. Vaccines can be developed ethically using no cells or cells from animals, insects, chicken eggs, or yeast. Do COVID vaccines being developed in Operation Warp Speed use fetal cell lines? Six vaccines do not use fetal cell lines. Two vaccines do, using the historically derived fetal cell lines HEK293 and PER.C6. Table: Vaccines being developed in Operation Warp Speed Sponsor(s) Type of Vaccine Production Astrazeneca & Univ. Oxford Adenovirus carrier ❌ HEK293 abortion-derived cell line Janssen and Johnson & Adenovirus carrier ❌ PER.C6 abortion-derived cell line Johnson VSV (animal virus) Merck and IAVI ✅ Vero monkey cells carrier Novavax Protein vaccine ✅ Sf9 insect cells Sanofi and GSK Protein vaccine ✅ Sf9 insect cells Moderna with NIAID mRNA vaccine ✅ No cells used Pfizer and BioNTech mRNA vaccine ✅ No cells used Inovio Pharmaceuticals DNA vaccine ✅ No cells used In order to increase the rates of COVID vaccination among the public, many of whom are opposed to the use of fetal cell lines, policymakers may want to encourage the production and availability of vaccines that do not use fetal cell lines.
    [Show full text]
  • 0 January to July 2021
    0 www.journalsofindia.com January to July 2021 SCIENCE & TECH ............................................................................................................................................................... 6 1. REUSABLE LAUNCH VEHICLE TECHNOLOGY DEMONSTRATION PROGRAMME(RLV-TD) ................................................. 6 2. GAGANYAAN MISSION ..................................................................................................................................................... 6 3. MARS ORBITER MISSION (MOM) ..................................................................................................................................... 6 4. CHANDRAYAAN MISSION................................................................................................................................................. 7 5. SOLAR MISSION ............................................................................................................................................................... 8 6. ARTEMIS ACCORD ............................................................................................................................................................ 9 7. NATIONAL MISSION ON INTERDISCIPLINARY CYBER-PHYSICAL SYSTEM (NMICPS) ....................................................... 10 8. SMART ANTI-AIRFIELD WEAPON (SAAW) ...................................................................................................................... 10 9. AQUAPONICS ................................................................................................................................................................
    [Show full text]
  • Infectious Diseases
    2013 MEDICINES IN DEVELOPMENT REPORT Infectious Diseases A Report on Diseases Caused by Bacteria, Viruses, Fungi and Parasites PRESENTED BY AMERICA’S BIOPHARMACEUTICAL RESEARCH COMPANIES Biopharmaceutical Research Evolves Against Infectious Diseases with Nearly 400 Medicines and Vaccines in Testing Throughout history, infectious diseases hepatitis C that inhibits the enzyme have taken a devastating toll on the lives essential for viral replication. and well-being of people around the • An anti-malarial drug that has shown Medicines in Development world. Caused when pathogens such activity against Plasmodium falci- For Infectious Diseases as bacteria or viruses enter a body and parum malaria which is resistant to multiply, infectious diseases were the current treatments. Application leading cause of death in the United Submitted States until the 1920s. Today, vaccines • A potential new antibiotic to treat methicillin-resistant Staphylococcus Phase III and infectious disease treatments have proven to be effective treatments in aureus (MRSA). Phase II many cases, but infectious diseases still • A novel treatment that works by Phase I pose a very serious threat to patients. blocking the ability of the smallpox Recently, some infectious pathogens, virus to spread to other cells, thus 226 such as pseudomonas bacteria, have preventing it from causing disease. become resistant to available treatments. Infectious diseases may never be fully Diseases once considered conquered, eradicated. However, new knowledge, such as tuberculosis, have reemerged new technologies, and the continuing as a growing health threat. commitment of America’s biopharma- America’s biopharmaceutical research ceutical research companies can help companies are developing 394 medicines meet the continuing—and ever-changing and vaccines to combat the many threats —threat from infectious diseases.
    [Show full text]
  • Vaxart, Inc. Signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP
    6/25/2020 Print - Vaxart, Inc. Signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP Source: Vaxart, Inc. June 25, 2020 08:00 ET Vaxart, Inc. Signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year Through Large Scale Lyophilization, Tableting and Coating SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that it signed a Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP (AMS) affirming the parties’ intent to establish AMS as a resource for lyophilization development and large scale manufacturing including tableting and enteric coating for Vaxart’s oral COVID-19 vaccine. AMS will be assigning dedicated resources and equipment for the scale up and commercial production of the vaccine upon entering a formal agreement. “We believe AMS’ experience coupled with its ability to manufacture a billion or more doses per year would be a beneficial addition to our group of CDMO partners and enable the large scale manufacturing and ultimate supply of our COVID-19 vaccine for the US, Europe and other countries in need,” said Andrei Floroiu, CEO of Vaxart Inc. “We believe our oral vaccines, generated on our proven platform, have the potential to offer superior protection against airborne viruses such as SARS-CoV-2 by triggering both mucosal and systemic immunity while being administered by a room temperature-stable tablet, an enormous logistical advantage in large vaccination campaigns.” About Vaxart Vaxart is a clinical-stage biotechnology company focused on developing oral tablet vaccines designed to generate mucosal and systemic immune responses that protect against a wide range of infectious diseases and has the potential to provide sterilizing immunity for diseases such as COVID-19.
    [Show full text]
  • Vaccine Formulations for Protection Against Covid-19 Infection
    VACCINE FORMULATIONS FOR PROTECTION AGAINST COVID-19 INFECTION KRISTY M. AINSLIE, Professor and Vice Chair, Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina January 18, 2021 PATH TO SARS-CoV-2 PANDEMIC 2003 2012 2019 Wuhan, China, severe Before 2003 only twelve Severe acute respiratory Middle East respiratory acute respiratory animal or human syndrome coronavirus syndrome coronavirus syndrome coronavirus 2 coronaviruses were (SARS-CoV) (MERS-CoV) (SARS-CoV-2) emerged identified 8096 cases and 774 2,442 cases and 842 >78M cases and >1.7M deaths deaths deaths SARS-CoV-2 likely crossed over from bats at a wet market in Wuhan, although Pangolin’s are also likely a host. Kristy Ainslie, PhD – UNC Eshelman School of Pharmacy – Jan 18, 2021 SARS-CoV-2 BINDS THROUGH SPIKE PROTEIN TO ACE2 RBD: Receptor Binding domain NTD: N-terminal domain CTD: C-terminal domain S protein: Spike protein ACE2: Angiotensin-converting enzyme 2 - Host receptor where spike protein binds Kristy Ainslie, PhD – UNC Eshelman School of Pharmacy – Jan 18, 2021 COVID-19 IMMUNOPATHOLOGY SARS-CoV-2 infection Can include hyper-immune responses is thought to act in • A cytokine storm that leads to immune cell infiltration of the lungs part through antibody- • Alveolar damage can lead to pulmonary failure dependent • Can result in acute respiratory distress syndrome (ARDS) enhancement (ADE). Non-neutralizing antibodies formed after infection or vaccination could lead to enhanced virus uptake in cells. ADE with SARS-CoV- 2 infection has not been characterized in humans. Kristy Ainslie, PhD – UNC Eshelman School of Pharmacy – Jan 18, 2021 Image: Ulrich et al.
    [Show full text]
  • Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines
    Review Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines Ekramy E. Sayedahmed 1 , Ahmed Elkashif 1, Marwa Alhashimi 1, Suryaprakash Sambhara 2,* and Suresh K. Mittal 1,* 1 Department of Comparative Pathobiology, Purdue Institute for Immunology, Inflammation and Infectious Disease, Purdue University Center for Cancer Research, College of Veterinary Medicine, Purdue University, West Lafayette, IN 47907, USA; [email protected] (E.E.S.); [email protected] (A.E.); [email protected] (M.A.) 2 Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA * Correspondence: [email protected] (S.S.); [email protected] (S.K.M.) Received: 2 August 2020; Accepted: 17 September 2020; Published: 1 October 2020 Abstract: Ever since the discovery of vaccines, many deadly diseases have been contained worldwide, ultimately culminating in the eradication of smallpox and polio, which represented significant medical achievements in human health. However, this does not account for the threat influenza poses on public health. The currently licensed seasonal influenza vaccines primarily confer excellent strain-specific protection. In addition to the seasonal influenza viruses, the emergence and spread of avian influenza pandemic viruses such as H5N1, H7N9, H7N7, and H9N2 to humans have highlighted the urgent need to adopt a new global preparedness for an influenza pandemic. It is vital to explore new strategies for the development of effective vaccines for pandemic and seasonal influenza viruses. The new vaccine approaches should provide durable and broad protection with the capability of large-scale vaccine production within a short time. The adenoviral (Ad) vector-based vaccine platform offers a robust egg-independent production system for manufacturing large numbers of influenza vaccines inexpensively in a short timeframe.
    [Show full text]
  • An Effective Strategy of Human Tumor Vaccine Modification by Coupling
    An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules Claudia Haas,1 Christel Herold-Mende,2 Roswitha Gerhards,3 and Volker Schirrmacher1 1German Cancer Research Center, Tumor Immunology Program, Heidelberg, Germany; 2Department of Neurosurgery, University-Clinic, Heidelberg, Germany; and 3Marien-Hospital, Herne, Germany. A new, generally applicable procedure is described for the introduction of defined costimulatory molecules into human cancer cells to increase their T-cell stimulatory capacity. The procedure involves infection with Newcastle disease virus to mediate the cell surface binding of costimulatory molecules (e.g., specially designed bispecific antibodies (bsAb)). The modification is independent of tumor cell proliferation and laborious recombinant gene technology and can be applied directly to freshly isolated and g-irradiated patient-derived tumor cells as an autologous cancer vaccine. Following the infection of tumor cells with a nonvirulent strain of Newcastle disease virus, the cells are washed and then further modified by coincubation with bsAbs, which attach with one arm to the viral hemagglutinin-neuraminidase (HN) molecule on the infected tumor cells. The second specificity of one bsAb (bs HN 3 CD28) is directed against CD28 to augment antitumor T-cell responses by selectively channeling positive costimulatory signals via the CD28 pathway. A second bsAb (bs HN 3 CD3) was produced to deliver T-cell receptor-mediated signals either alone (bsCD3 vaccine) or in combination with anti-CD28 (bsCD3 vaccine plus bsCD28 vaccine). In human T-cell stimulation studies in vitro, the bsCD28 vaccine caused an up-regulation of early (CD69) and late (CD25) T-cell activation markers on CD4 and CD8 T lymphocytes from either normal healthy donors or cancer patients (autologous system) and induced tumor cytostasis in nonmodified bystander tumor cells.
    [Show full text]
  • Edição Atualizada Em 30/11/2020
    30 | NOVEMBRO | 2020 Edição atualizada 30 | NOVEMBRO | 2020 Edição atualizada 2020 Ministério da Saúde. Todos os direitos reservados. É permitida a reprodução parcial ou total desta obra desde que citada a fonte e que não seja para venda ou qualquer fim comercial. Venda proibida. Distribuição gratuita. Versão eletrônica disponível em: https://coronavirus.saude.gov.br/ Elaboração, distribuição e informações: MINISTÉRIO DA SAÚDE Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde Departamento de Ciência e Tecnologia Esplanada dos Ministérios, Bloco G, Ed. Sede, Sobreloja CEP: 70.058-900 – Brasília/DF Tels.: (61) 3315-7990/9227 Site: www.saude.gov.br/sctie E-mail: [email protected] Supervisão geral: Hélio Angotti Neto – Secretário de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde (SCTIE/MS) Camile Giaretta Sachetti – Diretora do Departamento de Ciência e Tecnologia (Decit/SCTIE/MS) Patrícia de Souza Boaventura - Coordenadora-Geral de Ações Estratégicas em Pesquisa Clínica (CGPCLIN/Decit/SCTIE/MS) Priscilla Azevedo Souza – Coordenadora-Geral de Ações Estratégicas em Pesquisa Clínica - Substituta (CGPCLIN/Decit/SCTIE/MS) Elaboração e organização: Evandro de Oliveira Lupatini – CGPCLIN/Decit/SCTIE/MS Felipe Fagundes Soares – CGPCLIN/Decit/SCTIE/MS Felipe Nunes Bonifácio – CGPCLIN/Decit/SCTIE/MS Glícia Pinheiro Bezerra – CGPCLIN/Decit/SCTIE/MS João Paulo Alves Oliveira – CGPCLIN/Decit/SCTIE/MS Junia Carolina Rebelo dos Santos Silva – CGPCLIN/Decit/SCTIE/MS Karla Andreia Mette Waldrich Tauil –
    [Show full text]
  • Vaccines in Development to Target COVID-19 Disease April 9, 2020
    Vaccines in Development to Target COVID-19 Disease April 9, 2020 BACKGROUND development, including funding research into the development and use of platform technologies and investigational vaccines Since its emergence in December 2019 in Wuhan, China, the against novel pathogens.6 Given the abundance of vaccines under SARS-CoV-2 virus has caused more than 1.3 million cases and development, this fact sheet will focus on the vaccine candidates nearly 75,000 deaths globally as of April 06, 2020.1 Currently, for which research is currently being funded at least in part by no vaccine or proven treatment exists for this virus or any CEPI, as well as candidates that are undergoing clinical trials. coronavirus. The rapid spread and unprecedented dramatic rise Vaccine candidates are listed by developer below. of COVID-19 deaths and cases has led many research groups worldwide to explore potential vaccine candidates against SARS-CoV-2.2 The World Health Organization (WHO) has Phase I Clinical Trials worked to develop a Research and Development Blueprint that outlines key areas for research and innovation to address gaps • CanSino Biological, Inc., and Beijing Institute of in controlling COVID-19.3 Additionally, as of April 4, 2020, Biotechnology WHO has identified more than 60 vaccine candidates currently CanSino Biological, Inc., a China-based company, is being investigated against the SARS-CoV-2 virus across a range collaborating with the Beijing Institute of Biotechnology to of platforms, including nucleic acid, live attenuated, protein develop a nonreplicating viral vector vaccine2 and has recently subunit, and viral vector (Table 1).2 Of these, 2 are undergoing begun phase I clinical trials, with more than 100 participants 7,8 phase 1 clinical trials, while the remaining candidates are aged 18 to 60 years old, in a hospital located in Wuhan, China.
    [Show full text]
  • Inovio Welcomes Biotech Leader to Its Board of Directors
    NEWS RELEASE Inovio Welcomes Biotech Leader to its Board of Directors 1/15/2020 Inovio also announces retirement of long-serving board member PLYMOUTH MEETING, Pa., Jan. 15, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the appointment of Jay Shepard to its Board of Directors. Mr. Shepard brings broad healthcare and nancial experience to the board given his tenure as CEO of several biotech companies, his multiple corporate board appointments and his expertise as a healthcare venture capitalist. Dr. J. Joseph Kim, Inovio's President & CEO said, "We are fortunate to have Jay Shepard join Inovio's Board of Directors. Jay's expertise in health care, corporate nancing and M&A in the industry will be an asset to our company as we execute on our strategic deliverables in the next year and the next decade." Inovio also announced the retirement of Mort Collins from its Board. Dr. Collins had been a founding Board member of Inovio's predecessor, VGX Pharmaceuticals. Regarding Mort Collins, Dr. Kim said, "For nearly two decades Mort has been a guiding hand for Inovio helping us grow and make the right choices in science and business. For me, Mort has been more than a corporate board member. He has been a mentor to me and a strong voice I've relied on to manage innovation as we develop and commercialize our DNA medicines." About Jay Shepard Mr. Shepard is currently Non-executive Chairman and formerly President and Chief Executive Ocer of Aravive, a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life- threatening diseases, including cancer and brosis.
    [Show full text]
  • Immunology 101
    Immunology 101 Justin Kline, M.D. Assistant Professor of Medicine Section of Hematology/Oncology Committee on Immunology University of Chicago Medicine Disclosures • I served as a consultant on Advisory Boards for Merck and Seattle Genetics. • I will discuss non-FDA-approved therapies for cancer 2 Outline • Innate and adaptive immune systems – brief intro • How immune responses against cancer are generated • Cancer antigens in the era of cancer exome sequencing • Dendritic cells • T cells • Cancer immune evasion • Cancer immunotherapies – brief intro 3 The immune system • Evolved to provide protection against invasive pathogens • Consists of a variety of cells and proteins whose purpose is to generate immune responses against micro-organisms • The immune system is “educated” to attack foreign invaders, but at the same time, leave healthy, self-tissues unharmed • The immune system can sometimes recognize and kill cancer cells • 2 main branches • Innate immune system – Initial responders • Adaptive immune system – Tailored attack 4 The immune system – a division of labor Innate immune system • Initial recognition of non-self (i.e. infection, cancer) • Comprised of cells (granulocytes, monocytes, dendritic cells and NK cells) and proteins (complement) • Recognizes non-self via receptors that “see” microbial structures (cell wall components, DNA, RNA) • Pattern recognition receptors (PRRs) • Necessary for priming adaptive immune responses 5 The immune system – a division of labor Adaptive immune system • Provides nearly unlimited diversity of receptors to protect the host from infection • B cells and T cells • Have unique receptors generated during development • B cells produce antibodies which help fight infection • T cells patrol for infected or cancerous cells • Recognize “foreign” or abnormal proteins on the cell surface • 100,000,000 unique T cells are present in all of us • Retains “memory” against infections and in some cases, cancer.
    [Show full text]
  • Journal of Vaccines & Vaccination
    ccines & a V f V a o c l c i a n n a r t u i o o n J Ching, et al., J Vaccines Vaccin 2014, 5:6 Journal of Vaccines & Vaccination DOI: 10.4172/2157-7560.1000257 ISSN: 2157-7560 Research Article Open Access Evaluation of a Recombinant Vaccine Candidate r56Lc-1 in a Chigger Challenge Mouse Model Wei-Mei Ching1,3*, Woradee Lurchachaiwong2, Zhiwen Zhang1,3 Temitayo Awoyomi1,3, Chien-Chung Chao1,3 and Anthony Schuster2 1Viral and Rickettsial Diseases Department, Infectious Diseases Directorate, Naval Medical Research Center, Silver Spring, USA 2Entomology Department, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand 3Uniformed Services University of the Health Sciences, Bethesda, USA *Corresponding author: Wei-Mei Ching, PhD, Viral and Rickettsial Diseases Department, Infectious Diseases Directorate, Naval Medical Research Center, 503 Robert Grant Ave, RM3N71, Silver Spring, MD 20910, USA, Tel: 301 319 7438; Fax: 301 319 7451; E-mail: [email protected] Received date: 15 Sep 2014; Accepted date: 24 Oct 2014; Published date: 27 Oct 2014 Copyright: © 2014 Ching WM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Scrub typhus, an acute, febrile disease is transmitted by the bite of an Orientia infected chigger. We evaluated the protective potential of a recombinant 56 kDa antigen in a chigger challenge mouse model which mimics the natural transmission of Orientia. Chiggers from an L.
    [Show full text]